Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J M Walenga

Showing results (91-100 of 196) with videos related to

Pageof 20
Sort By:
The Annals of Thoracic Surgery|February 1, 1991
Potential use of recombinant hirudin as an anticoagulant in a cardiopulmonary bypass modelJ M Walenga, M Bakhos, H L Messmore, et al.
Thrombosis Research|April 27, 2001
Inhibition of tissue factor-activated platelets by low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonistS Ahmad, W P Jeske, Q Ma, et al.
Thrombosis Research|January 15, 1995
TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparinD A Hoppensteadt, J M Walenga, A Fasanella, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1993
Biochemical and pharmacologic profile of low molecular weight heparin (LU 47311, Clivarin)W Jeske, B Lojewski, J M Walenga, et al.
Advances in Experimental Medicine and Biology|January 1, 1983
Inhibition of bradykinin-induced contraction of isolated smooth muscle tissue preparations by oligopeptide thiobenzyl ester substrates for serine proteasesJ Fareed, G Kindel, J M Walenga, et al.
Clinical Chemistry|September 1, 1983
Molecular markers of hemostatic disorders: implications in the diagnosis and therapeutic management of thrombotic and bleeding disordersJ Fareed, R L Bick, G Squillaci, et al.
Thrombosis Research|August 15, 1993
The antithrombotic and anticoagulant effects of a synthetic tripeptide and recombinant hirudin in various animal modelsP Bacher, J M Walenga, O Iqbal, et al.
Thrombosis Research|August 7, 1998
Ethylenediaminetetraacetic acid (EDTA) in heparinE Coyne, H L Messmore, J M Walenga, et al.
Seminars in Thrombosis and Hemostasis|April 1, 1986
Molecular markers of hemostatic activation in atherosclerosis: a new concept in diagnostic profiling of endogenous pathophysiologic transitionJ Fareed, J M Walenga, W H Baker, et al.
Seminars in Thrombosis and Hemostasis|October 1, 1986
Evaluation of thrombin activity by immunoquantitation of fibrinopeptide A generationR M Emanuele, J Fareed, J M Walenga, et al.
Pageof 20

Showing results (91-100 of 196) with videos related to

Sort By:
Pageof 20
The Annals of Thoracic Surgery|February 1, 1991
Potential use of recombinant hirudin as an anticoagulant in a cardiopulmonary bypass modelJ M Walenga, M Bakhos, H L Messmore, et al.
Thrombosis Research|April 27, 2001
Inhibition of tissue factor-activated platelets by low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonistS Ahmad, W P Jeske, Q Ma, et al.
Thrombosis Research|January 15, 1995
TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparinD A Hoppensteadt, J M Walenga, A Fasanella, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1993
Biochemical and pharmacologic profile of low molecular weight heparin (LU 47311, Clivarin)W Jeske, B Lojewski, J M Walenga, et al.
Advances in Experimental Medicine and Biology|January 1, 1983
Inhibition of bradykinin-induced contraction of isolated smooth muscle tissue preparations by oligopeptide thiobenzyl ester substrates for serine proteasesJ Fareed, G Kindel, J M Walenga, et al.
Clinical Chemistry|September 1, 1983
Molecular markers of hemostatic disorders: implications in the diagnosis and therapeutic management of thrombotic and bleeding disordersJ Fareed, R L Bick, G Squillaci, et al.
Thrombosis Research|August 15, 1993
The antithrombotic and anticoagulant effects of a synthetic tripeptide and recombinant hirudin in various animal modelsP Bacher, J M Walenga, O Iqbal, et al.
Thrombosis Research|August 7, 1998
Ethylenediaminetetraacetic acid (EDTA) in heparinE Coyne, H L Messmore, J M Walenga, et al.
Seminars in Thrombosis and Hemostasis|April 1, 1986
Molecular markers of hemostatic activation in atherosclerosis: a new concept in diagnostic profiling of endogenous pathophysiologic transitionJ Fareed, J M Walenga, W H Baker, et al.
Seminars in Thrombosis and Hemostasis|October 1, 1986
Evaluation of thrombin activity by immunoquantitation of fibrinopeptide A generationR M Emanuele, J Fareed, J M Walenga, et al.
Pageof 20